Skip to main content

Niswender Laboratory

Discovery of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5

AUTHORS

Felts ASAndrew S , Rodriguez ALAlice L , Morrison RDRyan D , Blobaum ALAnna L , Byers FWFrank W , Daniels JSJ Scott , Niswender CMColleen M , Conn PJP Jeffrey , Lindsley CWCraig W , Emmitte KAKyle A . Bioorganic & medicinal chemistry letters. 2018 4 22; 28(10). 1679-1685

ABSTRACT

Based on previous work that established fused heterocycles as viable alternatives for the picolinamide core of our lead series of mGlu negative allosteric modulators (NAMs), we designed a novel series of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide mGlu NAMs. These new quinoline derivatives also contained carbon linkers as replacements for the diaryl ether oxygen atom common to our previously published chemotypes. Compounds were evaluated in a cell-based functional mGlu assay, and an exemplar analog 27 was >60-fold selective versus the other seven mGlu receptors. Selected compounds were also studied in metabolic stability assays in rat and human S9 hepatic fractions and exhibited a mixture of P450- and non-P450-mediated metabolism.

Tags: